AGILE THERAPEUTICS INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Revenues, net
Cost of product revenues
Gross profit
Operating expenses:
Research and development
Selling and marketing
General and administrative
Restructuring costs
Loss on disposition of assets
Total operating expenses

Loss from operations
Other income (expense)
Interest income
Interest expense
Unrealized gain on warrant liability
Total other income (expense), net
Loss before benefit from income taxes
Benefit from income taxes
Net loss
Net loss per share (basic and diluted) (in dollars per share)
Weighted-average common shares (basic and diluted) (in shares)
Other comprehensive income:
Unrealized (loss) on marketable securities
Comprehensive loss
Net loss per share (basic) (in dollars per share)
Net loss per share (diluted) (in dollars per share)
Weighted-average common shares (basic) (in shares)
Weighted-average common shares (diluted) (in shares)

Comments